The Potential Use of Metabolic Cofactors in Treatment of NAFLD

• Non-alcoholic fatty liver disease (NAFLD) is caused by the imbalance between lipid deposition and lipid removal from the liver, and its global prevalence continues to increase dramatically. NAFLD encompasses a spectrum of pathological conditions including simple steatosis and non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer. Even though there is a multi-disciplinary effort for development of a treatment strategy for NAFLD, there is not an approved effective medication available. Single or combined metabolic cofactors can be supplemented to boost the metabolic processes altered in NAFLD. Here, we review the dosage and usage of metabolic cofactors including l-carnitine, Nicotinamide riboside (NR), l-serine, and N-acetyl-l-cysteine (NAC) in human clinical studies to improve the altered biological functions associated with different human diseases. We also discuss the potential use of these substances in treatment of NAFLD and other metabolic diseases including neurodegenerative and cardiovascular diseases of which pathogenesis is linked to mitochondrial dysfunction.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Keyword

NAFLD

metabolic cofactors

l-carnitine

nicotinamide riboside

l-serine

N-acetyl-l-cysteine

SIMONE C

1994

AIDS

V8

P655 rdinoglu Adil

2015

SCIENTIFIC REPORTS

V5

laguarnera Mariano

2010

AMERICAN JOURNAL OF GASTROENTEROLOGY

V105

P1338 rk Michael

2013

TRENDS IN PHARMACOLOGICAL SCIENCES

V34

P167 odes Kate

2017

SPORTS MEDICINE

V47

P1619 son J. K.

2014

FRONTLINE GASTROENTEROLOGY

V5

P277 oshbaten Manouchehr

2010

HEPATITIS MONTHLY

V10

P12 llatori Nazzareno

2009

BIOLOGICAL CHEMISTRY

V390

P191 stee Quentin M.

2013

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY

V10

P330 rofalo Kevin

2011

JOURNAL OF CLINICAL INVESTIGATION

V121

P4735 idman Vera

2019

NEUROLOGY

V92

PE359 u Zhengtao

2017

HEPATOLOGY

V66

P1357 muk GE

2003

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

V18

P1220 rdinoglu Adil

2018

CELL SYSTEMS

V6

P7 rdinoglu Adil

2018

CELL METABOLISM

V27

P559 iels Martin

2015

FRONTIERS IN PHYSIOLOGY

V6

Koning TJ

2004

LANCET

V364

P2221 Koning TJ

2006

JOURNAL OF INHERITED METABOLIC DISEASE42nd Annual Meeting of the Society-for-the-Study-of-Inborn-Errors-of-Metabolism

SEP 06-09

2005

Paris

FRANCE

V29

P347

NAFLD

metabolic cofactors

l-carnitine

nicotinamide riboside

l-serine

N-acetyl-l-cysteine

fatty liver-disease

l-carnitine supplementation

n-acetylcysteine

oxidative stress

double-blind

glutathione

progression

prevalence

deficiency

impact

Nutrition & Dietetics

simone c

1994

aids

v8

p655

Publication and Content Type

ref (subject category)

for (subject category)